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Abstract
The human immunodeficiency virus type 1 (HIV-1) trans-activator of transcription protein Tat is
an important factor in viral pathogenesis. In addition to its function as the key trans-activator of
viral transcription, Tat is also secreted by the infected cell and taken up by neighboring cells where
it has an effect both on infected and uninfected cells. In this review we will focus on the relationship
between the structure of the Tat protein and its function as a secreted factor. To this end we will
summarize some of the exogenous functions of Tat that have been implicated in HIV-1
pathogenesis and the impact of structural variations and viral subtype variants of Tat on those
functions. Finally, since in some patients the presence of Tat-specific antibodies or CTL frequencies
are associated with slow or non-progression to AIDS, we will also discuss the role of Tat as a
potential vaccine candidate, the advances made in this field, and the importance of using a Tat
protein capable of eliciting a protective or therapeutic immune response to viral challenge.
Review
Introduction
Human immunodeficiency virus type 1 (HIV-1) exhibits
high genetic variability, with strains divided into three
main groups: major (M), which are the cause of most HIV-
1 infections worldwide, outlier (O) and new (N) that are
non M and non O [1]. Within group M, nine subtypes are
recognized, designated by the letters A-D, F-H, J and K. In
addition, circulating recombinant forms (CRF) have also
been identified [1]. Globally, over 50% of all infections
are caused by subtype C which is found mainly in sub-
Saharan Africa, India and South America, whereas subtype
B, the most studied clade, represents 10% of all infections,
and is dominant in both Europe and America. Subtypes A
and D are found in sub-Saharan Africa and account for
12% and 3% of infections respectively, while CRF_01_AE
is found mainly in south east Asia and represents 5% of all
infections worldwide [1]. Recent research has shown that
the different subtypes and CRF of HIV-1 have biological
differences with respect to transmission [2], replication
[3] and disease progression [4,5]. Moreover, the HIV-1
proteins gp120 [6], Nef [7], Vif, Vpr, Vpu [8,9] and Tat
[10-19] show clade and isotype-specific properties at both
the molecular and biological levels. Therefore, a generali-
zation of our understanding of HIV-1 subtype B transmis-
sion, pathogenesis and tissue involvement across all
subtypes is questionable.
The HIV-1 trans-activator of transcription (Tat) is an 86–
101 residue regulatory protein (9–11 kDa) that is essen-
tial for the productive and processive transcription from
the HIV-1 long terminal repeat (LTR) promoter [20-22].
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Tat binds to a short nascent stem-bulge loop leader RNA,
termed the trans-activation responsive region, or TAR
[23,24], that is present at the 5' extremity of all viral tran-
scripts via its basic region and recruits the complex of cyc-
lin T1 and cyclin-dependent kinase 9 (CDK9) forming the
positive transcription elongation factor B complex. CDK9
hyperphosphorylates the carboxy terminus domain of
RNA polymerase II, leading to the enhanced elongation of
transcription from the viral promoter. For Tat's transcrip-
tional activity, it has recently been reported that Tat is reg-
ulated by lysine methylation [25], and that it interacts
with a histone chaperone nucleosome assembly protein
[26].
In addition to its primary role as a transcriptional activa-
tor of viral gene expression, Tat is actively released from
unruptured, HIV-1-infected cells and is detectable in ex
vivo  culture supernatants and in the serum of HIV-1
infected individuals at concentrations up to 40 ng/mL
[27,28]. This exogenous Tat is able to enter both unin-
fected and latently infected cells, inducing apoptosis in
the former and activating the transcription of the viral
genome in the latter. The precise mechanism by which Tat
enters cells is under investigation and will not be dis-
cussed here. However, no specific receptor has been impli-
cated in the uptake of Tat and conflicting results have
been obtained for the involvement of macropinocytosis
[29], clathrin-mediated endocytosis [30] and caveolae/
lipid-raft-mediated endocytosis [31]. Thus, Tat fulfills a
role in HIV-1 pathogenesis not only as an essential pro-
tein for HIV-1 replication, but also as an extra-cellular
toxin [32]. Therefore, it is relevant to develop a vaccine
targeting Tat [33]. However, antibodies against Tat are
found in almost 50% of seropositive patients but are una-
ble to recognize Tat variants from all HIV-1 subtypes [17].
Moreover, these antibodies fail to slow disease progres-
sion to AIDS [34].
Understanding the structure-function relationship in
respect to the exogenous roles of Tat may have important
clinical implications, both for the development of new
vaccines against AIDS targeting Tat. Here, we present the
latest advances in elucidating the structure of Tat. We will
also summarize some of the roles exogenous Tat has been
shown to fulfill, and the impact that structural variations
of Tat may have on these functions. Finally, we will also
discuss the role of Tat as a potential vaccine candidate.
Structures of Tat variants
HIV-1 Tat is a small nuclear protein that exists predomi-
nantly in two different lengths – 86–87 residues or 99–
101 residues – and is encoded by two exons [20]. The long
99–101 residue forms are predominant in clinical isolates
from all HIV-1 subtypes excepted subtype D, which has a
non-synonymous single nucleotide polymorphism, creat-
ing a stop codon in the second exon encoding sequence.
However, some subtype B isolates have been found that
have this truncated form, and is the form of Tat most used
in research [15,20]. Tat is divided into six regions [35]
with the one termed the basic region being involved in
most of Tat's functions [20]. Nuclear magnetic resonance
spectroscopy (NMR) studies of biologically active Tat var-
iants revealed that the basic region and the other func-
tional regions are well exposed to solvent and surround a
core composed of part of the N-terminus, where the well
conserved Trp11 is found [36-38]. This folding is similar
between different Tat variants in aqueous solution but can
change dramatically when exposed to hydrophobic sol-
vents [10]. Tat is a flexible protein, and structural changes
are probably necessary for it to bind to its pharmacologi-
cal targets [39].
Primary structure
Tat was first described as a trans-activator of HIV-1 genes
[40]. Although trans-activation can be observed in vitro
with the first exon (residues 1–72), the second exon that
codes for 14 to 34 amino acids at the C-terminal extremity
is necessary to observe trans-activation in vivo [20]. Figure
1 shows a selection of Tat sequences obtained using solid
phase synthesis [10] that all have trans-activational tran-
scription activity (excepted Tat Oyi). This data show that
Tat can tolerate up to 40% sequence variation without loss
of activity [41].
Tat is divided into six different functional regions [35].
Region I (residues 1–21) is a proline-rich region and has
a conserved Trp11. Region II (residues 22–37) has seven
well conserved cysteines at positions 22, 25, 27, 30, 31, 34
and 37 except for subtype C which has a C31S mutation.
These cysteines appear to be free and no other cysteines
are found in the sequence except in CRF_01_AE (Figure 1)
and CRF_01_AG [42]. It was proposed that a functional
Tat could have cysteines bound to zinc [40]. The func-
tional test was the in vitro modulation of microtubule
assembly but a same effect is obtained with a Tat peptide
(residues 38–72) that does not contain the cysteine rich
region [18]. The trans activation assay in vivo with different
synthetic Tat variants does not require zinc binding [10].
Region III (residues 38–48) has a conserved Phe38 and the
conserved sequence 43LGISYG. Region IV (residues 49–
59) is rich in basic residues and has the rather well con-
served sequence 49RKKRRQRRRPP. Region V (residues
60–72) is the glutamine-rich region and has the highest
rate of sequence variation. Region VI constitutes the C-ter-
minus of Tat, is encoded by the second exon, and contains
a conserved RGD motif in subtypes B and D [20].
Secondary Structure
Circular dichroism reveals that the main secondary struc-
ture in aqueous solution is the β-turn with an average ofRetrovirology 2009, 6:50 http://www.retrovirology.com/content/6/1/50
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30% among Tat variants and almost no α-helix [10].
However, the secondary structures of Tat are dependent
upon its environment and change dramatically with an α-
helix becoming the main secondary structure in hydro-
phobic solvents [10]. These changes reveal that Tat is
highly flexible, and this is almost certainly related to the
capacity of Tat to cross cell membranes.
Peptides corresponding to the different Tat regions show
the same capacity of change in the secondary structures
with respect to its environment as the native protein [43].
However, regions I and VI are less flexible, probably due
to their high proline content (Figure 1). Interestingly,
region III seems to be the only one able to adopt a β-turn
structure independently from the other regions [43].
Chemical modification of the seven cysteines dramati-
cally changes the CD spectrum of Tat Bru (Figure 2)
revealing significant structural changes [10].
Tertiary structure
No X-ray crystallography structural studies of a full length
Tat have been performed, but four NMR studies of Tat var-
iants with two exons have been reported (Figure 3). The
first NMR structural study was performed under reducing
conditions using an 86-residue Tat Z2 variant in the pres-
ence of dithiothreitol (DTT) [44]. The oxidation state of
the cysteine residues is important when considering Tat's
trans-activational function as Tat becomes inactive when
incubated with strong reducing agents such as DTT or 2-
mercaptoethanol [45]. Furthermore, chemical modifica-
tion of cysteines changes dramatically the CD spectrum of
Tat [10]. Only 25 long distance NMR constraints, mainly
located in regions III and V were obtained in this study
[44]. Two later studies of the 86-residue Tat Bru [36] and
the 87-residue Tat Mal [37] were performed in the absence
of reducing agents and over 270 long-range NMR con-
straints were found in each. Both Tat proteins displayed
Tat sequences representative of the five main HIV-1 subtypes Figure 1
Tat sequences representative of the five main HIV-1 subtypes. The sequence length of Tat is variable and ranges from 
86 to 101 residues as a function of the second exon. A viable strain having only the first exon of Tat (72 residues) has never 
been observed in vivo. Subtype variability follows the geographical diversity of HIV-1 with subtype B Tat sequences being the 
most divergent compared to subtypes A, C, D and CRF_AE. These Tat variants have been synthesized using solid phase syn-
thesis and have been shown to be able to cross membranes and trans-activate the HIV-1 LTR except for Tat Oyi [10,14-
16,41,52].
Exon I 
1........10........20........30........40........50........60........70.
HXB2   MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQ 
Bru   .......................T..............T..................PP.G.....V..... 
Jr   ......S........................L......TK.G...............PP.D.....V..... 
Oyi   .....................SN.....R..L......TK.G................P.D.K...V..... 
93In   ......N....N..........N.......SY..L...QK.GL.............S.P.S.ED..NPI... 
96Bw   ......N...........R....K....Y..Y..L...Q..G..............STPPS.ES..NLI.E. 
92Br   ......N....N..........N.....R.SY..L...Q..G..............S.PPS.ED..NPIP.. 
Eli   .D....N....N......R.P.NK.H.....Y..P...LN.G..............GPP.GG.A..VPIP.. 
Mal   .D....N....N......R.P.NK.......Y...M.....G...............PP.GN.A..DP.PE. 
Z2   .D....NI...N..........NR.H.....Y.........G...............PS.GN....DPIP.. 
Ug05RP   ......SI...N......R.P.NK.......Y...L.....G................P.GD.A..VPIP.. 
Ug11LTS  ......N....N......S.P.NK.......Y...I.....G...............SP.GDH...DPIP.. 
Ug11RP   .D....NI...N......T.P.NK....V..Y..L...QS.G..............GPT.SNKQ..NPIP..
CM240   ..L...N....N......T...SK.......W...L..LK.G..........KH..GTP.S.KD..NPIP.. 
Exon II 
.......80.........90........100 Country    Clade
HXB2  PTSQPRGD-PTGPKE-KKKVERETETDPFD France    B 
Bru  ........-......   France    B 
Jr  .S..Q...-......S............DN USA    B 
Oyi  .A......-......S............E. Gabon    B 
93In  .LPRTP..-...SE.S.....SK.K..... India    C 
96Bw  .LPRTQ.N-...SE.S.....SK..A...A South  Africa  C 
92Br  .LP.T...-Q..SE.S.....SK....... Brazil    C 
Eli  .S......-......Q.....S.A....   DR  Congo   D 
Mal  .S..H...H......   DR  Congo   D 
Z2  .S......-......   DR  Congo   D 
Ug05RP  .S......-......   Uganda    D
Ug11LTS  .S......-......   Uganda    D 
Ug11RP  .IPRTQ.I-S...E.S.....DK....RR. Uganda    A
CM240  .LPII.RN-..D...S..E.ASKA...QC. Thailand   CRF_AE Retrovirology 2009, 6:50 http://www.retrovirology.com/content/6/1/50
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different folding to that of Bayer et al. [44] but similar to
each other. Tat Mal has a sequence similar to Tat Z2 (Fig-
ure 1), and the CD spectrum of Tat Z2 in the absence of
reducing agents is similar to that of both Tat Mal and Tat
Bru; both of which have been shown to be biologically
active in the absence of reducing agents. Therefore, it is
probable that the different folding observed in the NMR
study of Tat Z2 (Figure 3A) is due to a structural change
induced by the reducing conditions. An NMR study of a
reduced peptide corresponding to the first exon of Tat
(residues 1–72) combined with a His6 segment and T7
epitope that added 20 residues to the N-terminus result-
ing in a 92-residue peptide has also been performed
recently [46]. In this case, the authors were unable to iden-
tify NMR constraints and stated that Tat was a naturally
unfolded protein. It is surprising to deduce this statement
for all Tat variants from the study of a 72 residue reduced
Tat-His6T7 peptide as no viable HIV-1 strain consisting of
only the first exon of Tat has ever been observed in vivo.
Furthermore, the sequence used for this study does not
correspond to a viable HIV-1 strain, as the peptide con-
tained a supplemental 20 residues at the N-terminus that
are unrelated to Tat. The trans-activational activity of this
peptide was not tested or its ability to induce TNF produc-
tion from monocytes; so it is not possible to determine if
this study was biologically relevant. Moreover, a con-
served Tat folding is also confirmed by numerous vaccine
studies that raised antibodies against Tat conformational
epitopes in HIV-1-infected individuals and SHIV-1-
infected macaques [17,47-50]. Taken together, these find-
Circular dichroism (CD) spectra of Tat variants in aqueous  solution Figure 2
Circular dichroism (CD) spectra of Tat variants in 
aqueous solution. Tat Z2 (white triangle), Tat Oyi (black 
triangle), Tat Bru (white circle), Tat Bru cmC (no mark), Tat 
Jr (black circle), Tat Mal (white square) and Tat Eli (black 
square) were measured from 260 to 178 nm with a 50 μM 
path length in 20 mM phosphate buffer, pH 4.5. It is not pos-
sible to gather CD spectra into two categories composed of 
short Tat (white mark) or long Tat (black mark). The intense 
magnitude of the 200 nm band observed with Tat Bru cmC 
shows that chemical modifications of cysteines modify the 
folding of Tat.
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NMR studies of Tat proteins Figure 3
NMR studies of Tat proteins. Tat Z2 (A), Tat Bru (B), Tat 
Mal (C), and Tat Eli (D) 3D structures obtained from NMR 
constraints [36-38,44]. Region I is depicted in red, region II 
(cysteine-rich region) in orange, region III in yellow, region IV 
(basic region) in green, region V in light blue, region VI (resi-
dues 73–86/87) in blue and for Tat Eli the extra C-terminal 
residues are in pink. The Tat Z2 variant used had chemically 
modified cysteines which affected biological activity and 3D 
structure. The three Tat variants with biological activity (B, C 
and D) displayed a similar folding characterized by a core 
region composed of part of region I with the highly con-
served Trp11 while the functional region II, IV and V are well 
exposed to the solvent. The extra residues in the C-terminus 
of Tat Eli are exposed to the solvent and protrude from a 
groove between the basic region and the cysteine-rich 
region.
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ings indicate that Tat with its two exons should exist in a
stable conformation in vivo. Furthermore, the second exon
of Tat was is essential to get a biologically functional Tat
in a number of different assays [41,51-53]. Therefore, the
collective studies indicate that the second exon of Tat is
important to the stability of the structure. The last NMR
study of Tat to be reported was the first report of a NMR
structure for a full-length Tat and was performed using the
99-residue Tat Eli variant [38]. Figure 3D shows that Tat
Eli has a core region made up of a part of the N-terminus
with the highly conserved Trp11 and a folding similar to
Tat Bru and Tat Mal with the extra residues at the Tat Eli
C-terminus protruding from a groove between the basic
region and the cysteine-rich region that is well exposed to
solvent [38].
The main secondary structure building block in Tat vari-
ants is the β-turn [36-38]. The core of Tat is composed pri-
marily of aromatic residues organized in a hydrophobic
cluster involving the highly conserved Trp11 and Phe38,
with a part of region I adopting an extended structure that
crosses the protein and constitutes the core region, with
the other regions well exposed to the solvent packing
around the core. This core region might be involved in the
process that occur during Tat internalization and certainly
requires a structural change for this hydrophobic environ-
ment. The basic region (region IV) adopts an extended
structure while regions II, III, V and VI have β-turns except
for Tat Mal, which has an α-helix in region V. It is interest-
ing to note that the NMR spectra of Tat variants show a
low chemical shift dispersion indicative of a rather flexi-
ble structure, which might be a prerequisite for its ability
to cross membranes.
In conclusion, structural studies carried out on Tat vari-
ants with biological activity show that Tat variants have a
similar folding in aqueous solution characterized by a
core region composed of a part of region I, which is sur-
rounded by the other regions that are well exposed to sol-
vent. Mutations observed between Tat variants from
different HIV-1 subtypes induce local structural variations
such as the presence in region V of an α-helix in Tat Mal
instead of two β-turns in Tat Bru and Tat Eli. Tat is rather
flexible, and its folding can dramatically change between
aqueous and hydrophobic environments.
Extra-cellular functions of Tat
In addition to the major role of transcriptional activation
of viral gene expression, Tat has been implicated in a
number of extra-cellular functions during HIV-1 infec-
tion. Several studies have suggested that Tat plays a role in
viral infectivity and contributes to HIV-1 pathogenesis
[20]. For example, immature dendritic cells exposed to
exogenous Tat mature and upregulate key co-stimulatory
molecules such as CD40, CD80, CD86, lymphocyte func-
tion-associated antigens, major histocompatibility com-
plex (MHC) class I and II, lymphotoxin, chemokine (C-C
motif) ligand (CCL) 3, CCL4, CCL5, interleukin (IL)-12
and tumor necrosis factor (TNF) [51].
Interaction of Tat with integrins and its role in Kaposi's Sarcoma
The first extra-cellular role postulated for Tat was in its
direct contribution to Kaposi's sarcoma (KS) associated
with AIDS [27,53]. KS is an unusual neoplasm that is typ-
ically an indolent disease caused by the human herpesvi-
rus-8 (HHV-8), affecting the skin of elderly males, and is
not life threatening. However, AIDS-related KS (AIDS-KS)
is dramatically more frequent and more aggressive [54].
Early experiments with transgenic mice with the tat gene
showed that they rapidly developed dermal lesions resem-
bling KS [55]. Consistent with this finding, exogenous
subtype B Tat was shown to stimulate the growth of cells
of mesenchymal origin derived from Kaposi's sarcoma
lesions of AIDS patients, and was inhibited by anti-Tat
antibodies [27]. B Tat also induces the growth and loco-
motion of primary endothelial cells activated with inflam-
matory cytokines, in particular, interferon (IFN)-γ, TNF
and IL-1β, which are increased in the blood and lesions of
AIDS-KS individuals. IFN-γ, TNF and IL-1β also augment
the synthesis and release of basic fibroblast growth factor
(bFGF) from the spindle cells of KS lesions and induce its
production from endothelial cells [56,57]. In vivo, bFGF
exists primarily bound to heparan sulfate proteoglycans,
protected from proteolytic degradation, at the surface of
cells and extra-cellular matrix, with only a fraction being
found in soluble form. Tat, through its conserved basic
region, competes with bFGF for heparin-binding sites,
increasing soluble bFGF to concentrations that promote
spindle cell and endothelial cell growth [56,57] and
upregulates the integrins α5β1  and  αvβ3, receptors for
fibronectin and vitronectin, respectively, both of which
are highly expressed in AIDS-KS [58]. One of the similari-
ties between fibronectin, vitronectin and subtypes B and
D Tat is the presence in the C-terminal domain of Tat of
an RGD motif, which represents the principal cell attach-
ment moiety recognized by integrin receptors. Engage-
ment of integrins during endothelial cell adhesion
regulates their migration, tissue organization, matrix
remodeling, and, with receptors for soluble factors, sur-
vival, differentiation, and proliferation. Therefore, Tat, by
engaging with integrin receptors via its RGD motif, pro-
motes the locomotion of spindle cells and activated
endothelial cells and provides the adhesion signal they
require in order to grow in response to bFGF [59]. This
motif has also been implicated in inducing the migration
of monocytes and neutrophils through integrins α5β1 and
αvβ3 [60]. Mutations in this RGD motif or antibodies
derived against this motif prevent the attachment of Tat to
integrins [59]. Interestingly, not all Tat subtypes possesRetrovirology 2009, 6:50 http://www.retrovirology.com/content/6/1/50
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this motif, indicating possible subtype specific responses
to HHV-8 in HIV-1-infected individuals (Figure 1).
Tat and HIV-1 associated dementia
Tat is also a potent chemoattractant for macrophages and
monocytes and dendritic cells, but not lymphocytes
[16,61]. Region II of Tat has positions of amino acid sim-
ilarity with key residues in β-chemokines critical for
chemokine receptor binding and signal transduction [61],
including a CCF/Y motif at positions 30–32, a strongly
conserved Ile39 and a SYXR motif at position 46–49. B Tat
induces chemotaxis of monocytes, but not lymphocytes
through a CCR2-dependent mechanism that is dependent
upon the integrity of the 30CC motif of Tat [16,61]. The
C31S mutation found in C Tat variants abrogates its abil-
ity to act as a chemoattractant for monocytes as it fails to
bind CCR2 and induces a transient flux in cytosol Ca2+
[61].
The role of Tat in the development of neurocognitive
impairment remains controversial [62,63], but there is
evidence of Tat mediating neurotoxicity through its
regions II and IV [64,65]. Tat has been detected in post-
mortem HIV-1 encephalitic central nervous system (CNS)
tissue in various infected cells [66,67] as well as in unin-
fected oligodendrocytes [68]. It is interesting to note that
in India where the C subtype is prevalent, the HIV-1 asso-
ciated dementia is rare [69] and this could be due to the
C31S mutation [61]. Nevertheless, despite extensive in
vitro research and  in vivo animal studies demonstrating a
potential role for Tat in HIV-related CNS impairment, no
study to date has directly quantified the in vivo levels of
secreted Tat in the CNS as Tat is rapidly degraded post-
mortem [67]. In a mouse model of brain toxicity, after a
single intraventricular injection of Tat, macrophage infil-
tration, progressive glial activation, and neuronal apopto-
sis were observed over several days, while within 6 hours
Tat was undetectable [70]. Tat also crosses the blood-brain
barrier (BBB) and enters the CNS where it has toxic conse-
quences [71]. It interacts with microglia, astrocytes and
brain endothelial cells, increasing the expression of induc-
ible nitric oxide synthase and release of nitric oxide [72]
and TNF [14], as well as disrupting tight-junction distribu-
tion, increasing the blood brain barrier (BBB) permeabil-
ity [73]. Tat also exerts a neurotoxic effect on
hippocampal neurons by disinhibiting Ca2+-permeable
N-methyl-D-aspartate (NMDA) receptors from Zn2+-
mediated antagonism, thereby potentiating the NMDA-
mediated death [74]. Subtype C Tat is less neurotoxic than
subtype B Tat as a result of the C31S mutation with exper-
iments underway to explain this effect [13].
The influence of Tat on the transcription of TNF from
monocytes and microglial cells is particularly important
in HIV-1 pathogenesis [14] with patients suffering from
HIV-1-associated dementia (HAD) having increased
expression of TNF and TNF receptors on activated macro-
phages and monocytes in both the white matter of brain
tissue and sera [75]. TNF opens a paracellular route for
HIV invasion across the BBB [76], induces the expression
of adhesion molecules on astrocytes and endothelial cells
[77] and induces the release of chemokine factors from
monocytes and microglial cells allowing HIV-1 infected
monocytes and macrophages to transmigrate into the
CNS [75]. However, TNF also has neuroprotective effects,
such as upregulating the production of CCL5 from astro-
cytes and Bcl-2 from neurons [75], illustrating the multi-
factorial cause of the disease. B Tat upregulates TNF
production from microglial cells and monocytes through
a calcium dependent mechanism that involves an increase
in intracellular Ca2+  through L-type calcium channels
[14]. Subtype C Tat, which fails to induce an intracellular
calcium flux due to its C31S mutation, is still able to
induce TNF production, although at much reduced levels
[14]. The key checkpoint in TNF protein production in
monocytic cells is the transcriptional activation of the
gene where histone acetyltransferases and chromatin
remodeling play critical roles in enhanceosome formation
and are required for TNF gene activation. Both subtype B
and C Tat aid in these functions, but the mutation of F/
Y32W present in CRF_AE Tat interferes with chromatin
remodeling of the TNF locus and with the recruitment of
p300/CBP-associating factor to the TNF promoter, result-
ing in lower levels of TNF gene expression and protein
production in T cells [19]. The effect of CRF_AE Tat on
TNF production from monocytes has not yet been evalu-
ated.
Apoptosis and the role of Tat
The hallmark of disease progression in HIV-1 infected
individuals is an increased virus load [78] and the progres-
sive loss of CD4+ T cells [79]. Apoptosis, autophagy and
activation-induced cell death (AICD) are known to be
involved in this process [80-82]. Co-culture experiments
of HIV-1 infected and uninfected cells have shown that
while HIV-1-infected cells are resistant to HIV-induced
death, uninfected bystander CD4+ T cells undergo apopto-
sis [83]. Some studies have suggested that Tat induces
AICD and has no effect on resting CD4+ T cells [84,85],
whereas others have shown that activation is unnecessary
and Tat can directly induce apoptosis in resting CD4+ T
cells [14,15,86,87]. However, no study has addressed the
role autophagy may play in Tat-induced apoptosis,
although two Tat studies used serum deprivation as a
means to initiate apoptosis [14,15]. During starvation,
autophagy contributes to the maintenance of cellular
homeostasis by maintaining an amino acid reserve for
glucogenesis and for the synthesis of essential proteins by
targeting cell organelles and aggregates of long-lived pro-
teins for degradation and recycling. However, it may alsoRetrovirology 2009, 6:50 http://www.retrovirology.com/content/6/1/50
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result in autophagy-associated cell death [88]. The pro-
teins LC3B-II, Beclin I and ATG7 are essential for the lat-
ter. Beclin-1 possesses a BH3 domain that interacts with
the BH3 receptor domain of the anti-apoptotic proteins of
the Bcl-2 family. BH3-only proteins can induce autophagy
by competitively disrupting the interaction of Beclin-1
with Bcl-2/Bcl-XL, linking the apoptosis and autophagy
machinery. One such BH3-only protein, Bad, is known to
be activated upon the withdrawal of growth factors [88].
Tat also induces apoptosis by binding to tubulin at the
pharmacological site of paclitaxel, enhancing tubulin
polymerization [18] and preventing depolymerization
[89]. Tubulin polymers form microtubules necessary for
cellular morphology, intracellular organelle distribution,
chromosome migration during mitosis, cell differentia-
tion, as well as intracellular transport and signaling [90].
Inhibition of microtubule dynamics induces M arrest,
mitotic spindle assembly checkpoint activation, Bcl-2
phosphorylation, c-and Jun NH(2)-terminal kinase acti-
vation, leading to apoptosis. Furthermore, as microtu-
bules serve as scaffolds for signaling molecules that
regulate apoptosis, such as Bim, disruption of microtu-
bule dynamics releases these signaling molecules from
microtubules, which then induce mitochondrial mem-
brane permeabilization resulting in the release of critical
pro-apoptotic intermembrane space effectors into the
cytosol such as cytochrome c, apoptosis-inducing factor,
Smac/Diablo, Endo G, and pro-caspases [91]. Regions II
and III of Tat including the conserved Cys37 and Phe38 are
crucial to Tat-tubulin interactions [89]. This region differs
from those present in the tubulin-binding domains of
conventional microtubule-associated proteins, which typ-
ically contain positively charged residues [92]. It is possi-
ble that the basic region III of Tat provides the positive
charge necessary to neutralize the negatively charged C-
termini of tubulin promoting microtubule assembly. The
glutamine-rich region V may also play a role in providing
the structural conformation required for the Tat-tubulin
interaction [14]. In a study of two subtype D 86-residue
Tat proteins, it was found that mutations in this region
that disturb the formation of an α-helix reduced the abil-
ity of Tat to bind and polymerize tubulin [14]. Further evi-
dence for this interaction was provided in a comparison of
long versus short Tat in inducing CD4+ T cell apoptosis
[15]. The short form was less effective than the long form
[15]. In the NMR study of the full-length 99 residue Tat
Eli, the C-terminus of Tat masks the α-helix of the
glutamine-rich region [38], possibly reducing this Tat's
ability to bind to tubulin.
Tat is also capable of inducing apoptosis in Bim-/- cells
[89]. Another pathway by which Tat has been shown to
induce the apoptosis of bystander CD4+ T cells is by
upregulating Fas ligand (CD178) expression in both
infected and uninfected bystander cells [14,15,93]. HIV-1-
infected individuals have CD4+ and CD8+ T cells that are
more susceptible to CD178-induced apoptosis. Further-
more, CD4+ T cells from HIV-1-infected individuals over-
express Fas (CD95), and the proportion of these increases
with disease progression [94]. Therefore, the upregulation
of CD178 by Tat may lead to increased apoptosis in the
antigen-responding T cells that are overexpressing CD95
[94]. In the only comparison of long versus short Tat pro-
teins ability to induce CD4+ T cell apoptosis, it was shown
that the short 86-residue form of Tat upregulates more
CD178 mRNA leading to an increases in caspase-8 that
was not observed with the full length form [15], highlight-
ing the importance of the C-terminus of Tat.
Development of an HIV-1 vaccine using Tat
This review will focus on vaccine approaches using full
Tat. The difficulty in reviewing all the vaccine approaches
that have included Tat or parts of Tat with other HIV pro-
teins is to determine if the effect observed is related to Tat.
A good pharmaceutical practice should be to test each
active principle separately before testing together to see if
a synergic effect is possible. Furthermore it is important to
note that stability of a vaccine in solution for at least one
month is mandatory for a vaccination campaign. Adher-
ence to these criteria would reduce significantly the
number of vaccine projects actually developed against
AIDS and would allow one to focus on vaccines that have
a chance to be efficient in the field.
Biologically active Tat appears to be a safe approach as
indicated by safety studies carried out on monkeys in
which no local or systemic toxicity or adverse effects were
observed [95-99]. The two main vaccine strategies against
Tat up to now use a short, 86 residue version of a B-sub-
type European Tat variant that is either inactivated [95] or
has full activity [96]. These two approaches were tested on
macaques followed by a homologous SHIV-1 challenge
[96,100]. A significant decrease of viremia was observed
in these two studies carried out respectively on Cynomol-
gus [96] and Rhesus macaques [100], without showing
complete protection during primary infection. Another
study showed a long term control of infection following
SHIV-1 challenge on Tat vaccinated Cynomolgus
macaques [101].
Conflicting results regarding Tat vaccination
It is interesting to note that conflicting results appears in
Tat vaccine studies on macaques since no protection was
observed with a SIV challenge [102] or a vaccination with
a recombinant virus coding for a Tat-Rev protein [103].
These conflicting results could be explained by different
immunization regimens, viral stocks, routes of viral chal-
lenge, and animal species. The difference between SIV Tat
and HIV-1 Tat in the first study and the probability that aRetrovirology 2009, 6:50 http://www.retrovirology.com/content/6/1/50
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Tat-Rev recombinant protein does not have the native Tat
folding or the native Rev folding for the second study may
explain the absence of protection. More puzzling, how-
ever, are the results of two other studies using similar viral
vectors expressing Tat, Env and Gag that gave opposite
conclusions. One study showed the efficacy of vectored
Tat, but not Gag and Env [104], while another study
showed efficacy of vectored Gag and Env, but not Tat
[105]. The main difference in the two studies was that one
used a homologous challenge with the Tat Bru sequence
in both the vaccine and in the SHIV [104] while the other
used a heterologous challenge with the Tat Bru sequence
in the vaccine and Tat JR in the SHIV [105]. HIV-1 JR and
HIV-1 Bru are B subtypes (Figure 1), but their Tat
sequences have non-conservative mutations inducing
conformational changes [43]. Theses mutations between
the vaccine and the virus used for the challenge might
explain the lack of efficacy of the Tat vectored vaccine in
the second study [105]. The second study resembled more
closely reality since a vaccinated person would not likely
be exposed to a homologous virus infection. However, it
is not clear why the investigators in the same experiment
used a homologous Gag and Env [105].
Over the last 20 years, HIV-1 vaccine studies that target the
HIV-1 envelope proteins have been tested using a homol-
ogous SHIV/macaque model and have met with some suc-
cess [106]. However, this was not followed by success in
clinical trials [107]. This is likely due to the high genetic
diversity of HIV-1, and this is a reason why heterologous
SHIV challenge in macaques, with a genetically distinct
virus, should be used to determine if a vaccine can be
effective against HIV-1 infection in humans [106]. If a suc-
cessful homologous SHIV challenge is used to provide
support for Tat vaccination in vivo, then the development
of a worldwide Tat vaccine in humans need to addition-
ally take into account the genetic diversity of HIV-1 Tat
proteins. In this regard, it is important to note that immu-
nization with the B subtype Tat Bru does not stimulate an
efficient response against Tat variants from A and C sub-
types [41].
Tat antibodies in human sera
The interest in developing a Tat vaccine rose with the dis-
covery that seropositive long-term non-Progressor (LTNP)
patients had a higher level of Tat antibodies than seropos-
itive Rapid Progressor (RP) patients [49,50,95 ,108,110,
111]. It is notable that with a sera dilution of 1:1000, Tat
Bru is recognized by only 30% of the RP patients in
Europe [95] and only 10 to 14% of RP patients in Africa
[111]. This percentage can reach up to 50% in Africa if
other Tat variants from subtypes A, C and D are tested
[17]. This result outlines again how mutations in Tat var-
iants can affect immunogenicity, but it shows also that a
large amount of seropositive patients are unable to recog-
nize Tat. Furthermore Tat antibodies in African RP
patients have no effect on their progression to AIDS [34].
Thus for a majority of HIV-1 infected patients, Tat is not
recognized and although this protein is present in the cir-
culating of infected individuals, those who recognize Tat
can apparently not neutralize this protein.
Low cross recognition between Tat variants
Only region IV is well conserved among Tat variants (Fig-
ure 1), but this region is not recognized by sera from HIV-
1 infected patients [17]. Why the basic region of Tat is not
recognized by the human immune system could be due to
sequence similarity of the basic region of Tat
(48GRKKRRQRRR) with epitopes found in human pro-
teins such as protamine (24RSCRRRKRRSCR). It is inter-
esting to note that two thirds of new born children from
HIV-1 infected mother succeed to escape HIV-1 infection
that can occur during the delivery or the breastfeeding and
generally sero-revert when they are eighteen months old
[112]. This high proportion excludes genetic factors that
could be due to an innate immunity against HIV. It could
be possible that a repression of the immune system to rec-
ognize Tat may exist in adults, but not among new born
children since the full expression of protamine arrives
with sexual maturation.
In the other Tat regions that appear to be recognized by
the immune system, a high level of mutations exists since
40% of Tat can be mutated without loss of activity [17]. It
is clear that the discrepancy in two studies on the same
cohort regarding the number of patients who recognize
Tat in Uganda [17,111] is related to the absence of cross
recognition by antibodies to African Tat variants when
they used to detect an European Tat variant [111]. This
finding was previously reported with vaccination of rab-
bits with different Tat variants [41], and it illustrated that
a Tat vaccine using a European variant would be ineffi-
cient in Africa where the majority of the HIV infected indi-
viduals are located.
Innate and acquired immunity
More attention should be placed on the natural immunity
against HIV. Natural immunity against HIV-1 is observed
in a low proportion of the human population and encom-
passes different mechanisms ranging from chemokine
mutations to the capacity to produce neutralizing anti-
bodies against the HIV-1 envelope [112,113]. Natural
immunity can be innate or acquired, the latter being of
course the most interesting for vaccine development.
Patients with natural immunity against HIV-1 can be
exposed and still remain persistently seronegative (EPS),
or they can be seropositive and remain long term non pro-
gressors (LTNP). In most cases, this natural immunity
turns out to reflect innate immunity. However, there is a
very rare category of EPS patients highly exposed to theRetrovirology 2009, 6:50 http://www.retrovirology.com/content/6/1/50
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virus who are resistant to HIV-1 due apparently to an
acquired immunity. This was revealed by EPS patients in
Kenya who were sex workers and who became seroposi-
tive and then developed AIDS after a lapse in sex work,
showing that their former resistance to HIV-1 was not
innate [114]. Kenyan sex workers who are EPS had been
intensely studied, and their resistance to HIV-1 appears to
be related to their capacity to develop an efficient CD8 T
cell response against HIV-1 [115]. However, the paradox
is that the CD8 T cell response in EPS Kenyan sex workers
is five times lower in magnitude than that of seropositive
Kenyan sex workers who ultimately develop AIDS [116].
To make things even more puzzling, studies of similar
cohorts of EPS individuals in Ivory Cost, Vietnam and
Cambodia show that they have no HIV-1 specific CD8 T
cell response but do have natural killer (NK) cell
responses [117,118], antibodies against HIV-1 envelop
proteins [119], or cellular factors that affect steps of viral
entry [120].
Acquired immunity against HIV-1 in a cohort in Gabon
During the eighties in Africa, it was observed in a remote
area of Gabon called "Haut Ogooué" that seropositive
individuals were not developing AIDS and that they ulti-
mately could sero-revert [121,122]. An epidemiological
survey was designed and carried out on 750 pregnant
women for two years, and 25 were identified as seroposi-
tive [122]. From these 25 seropositive women, 23 sero-
reverted and became EPS during the two years of the sur-
vey. Although EPS patients have normally no detectable
virus, it was possible to isolate and clone a HIV-1 strain
from one patient called Oyi when she was seropositive
[122]. Contrary to other EPS cohort of sex workers or drug
users that were constituted many years after the first expo-
sure to HIV, the Gabon cohort was constituted during the
primary infection, and this may explain why it was possi-
ble to clone a virus. All women infected with HIV-1 Oyi
sero-reverted but maintained a CTL response against HIV-
1 and had antibodies against P24 [122]. Some women
infected by HIV-1 Oyi were also infected by a highly viru-
lent strain similar to HIV-1 Eli [122]. The high proportion
of EPS phenotype in this cohort (92%) indicated that the
resistance to HIV-1 was probably due to an acquired
immunity and not an innate immunity that is statistically
observed in less than 5% of the population. Ten years after
the publication of the above study, the 23 women
remained in good health and traces of HIV-1 infection
were no longer detectable in their blood (Eric Delaporte,
personal communication). It is interesting to note that
HIV-1 infection appears to be very low in Gabon com-
pared to other central African countries [123].
HIV-1 Oyi has genes similar to regular HIV-1 strains
except the tat gene, which has mutations never found in
other Tat variants [43]. Immunization with Tat Oyi raises
antibodies in rabbits that were able to recognize different
Tat variants even with mis-matched amino acids of up to
38%; this phenomenon has not been seen from immuni-
zation with other Tat variants [41]. Tat Oyi appears to
induce a humoral immune response against a three-
dimensional epitope that is conserved in other Tat vari-
ants, and this humoral response could make it possible to
neutralize extracellular Tat. Recently, it was shown that
Tat Oyi immunization of macaques induced a predomi-
nant Th2 immune response while a predominant Th1
immune response was commonly observed after immuni-
zation with a non-Oyi Tat [124].
The role of extracellular Tat was not known during the
nineteen eighties, and the presence of antibodies against
Tat was not tested in this Gabon cohort [122]. However,
we recently were able to detect Tat antibodies in a cohort
of EPS patients in Vietnam (data not published). Two
third of the patients had Tat antibodies characterized by
the capacity to recognize Tat variants from the five main
HIV-1 subtypes (data not published), while RP seroposi-
tive patients recognized mainly Tat variants from one or
two HIV-1 subtypes [17].
Heterologous SHIV challenge after vaccination with Tat Oyi
Seven rhesus macaques were immunized with synthetic
Tat Oyi complemented with an adjuvant, and then a het-
erologous challenge with the European SHIV BX08 was
carried out on Tat Oyi vaccinated macaques and control
macaques. Tat Oyi vaccinated macaques had lower
viremia compared with control macaques. The most inter-
esting finding was that SHIV infected cells were no longer
detectable at 8 weeks post-challenge in Tat Oyi vaccinated
macaques. Surprisingly, the macaque that had the lowest
viremia had no antibodies against SHIV envelop proteins.
This macaque was challenged again, and the animal expe-
rienced a short period of seropositivity and sero-reverted
[47]. It was, therefore, possible to reproduce experimen-
tally in vivo what is observed in the field with EPS patients.
This experiment of heterologous SHIV challenge after Tat
Oyi vaccination shows that it could be possible to dramat-
ically reduce the level of HIV infected cells in HIV infected
patients. Of note, this goal has never been achieved with
antiviral treatments.
As a conclusion, a vaccine approach using Tat should take
in account the mutations that can occur in Tat variants.
Conformational epitopes are essential to obtain cross rec-
ognition of Tat variants and therefore a full Tat protein
with the second exon to have the right folding. The second
exon of Tat elicits immunity against Tat [125], and a long
form of the second exon improves cross recognition of Tat
variants [52]. However, up to now, only the immuniza-
tion with a sequence related to the Tat Oyi variant makes
possible the cross recognition of Tat variants from theRetrovirology 2009, 6:50 http://www.retrovirology.com/content/6/1/50
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main HIV-1 subtypes, which appears to be one of the
characteristics observed with antibodies able to neutralize
Tat extra cellular functions.
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